Serum p53 antibodies in patients affected with ulcerative colitis

被引:18
|
作者
Cioffi, M
Riegler, G
Vietri, MT
Pilla, P
Caserta, L
Carratù, R
Sica, V
Molinari, AM
机构
[1] Second Sch Med, Dept Gen Pathol, Naples, Italy
[2] Second Sch Med, Gastroenterol Hlth Serv, Naples, Italy
关键词
anti-p53; antibodies; colorectal cancer; ulcerative colitis;
D O I
10.1097/00054725-200409000-00016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
During tumor progression, the accumulation in genetic alterations is a fundamental characteristic of malignant cells. p53 gene is frequently mutated in human tumor. Cellular accumulation of p53 protein can initiate an immune response with generation of circulating anti-p53 antibodies. Patients with ulcerative colitis have an increased risk of developing colorectal neoplasm and, among the different genes involved in carcinogenesis, p53 may play a key role. Sera and tissues from 97 patients (M = 53, F = 44) affected with ulcerative colitis (UC) were collected. Serum anti-p53 antibodies (p53Abs) were detected in duplicate with ELISA method. Serum p53Abs were detectable in 9.3% (9/97) of patients affected with UC. In these patients, the titer of p53Ab ranged between 3.1 and 14.9 U/mL (mean, 6.6 U/mL; SD, 4.64). Serum p53Abs were undetectable in control group. With an immunoluminometric assay for the quantitative determination of p53, we found 9/97 positive samples (greater than or equal to0.69 mg/mg of total proteins). In contrast, the samples of the remaining 89 patients were found negative (less than or equal to0.30 mg/mg of total proteins). All patients that were positive for anti-p53 antibodies were also positive with p53 protein accumulation in the tissue of colonic biopsies. In UC, follow-up with colonoscopy has several advantages. The colonoscopy is not well accepted by patients, and poor patient observance has the potential to seriously devalue the technique as a screening tool, despite practical considerations of competence within endoscopy service. Serological detection of p53Abs by enzyme-linked immunosorbent assay (ELISA) is easy to perform, does not require tumor specimen, can be performed in a routine diagnostic procedure, may be used in clinical practice, and could facilitate physicians in patient monitoring. We suggest that serum p53Abs assessment, indirect marker for p53 gene mutations, and abnormally high p53 protein levels could be considered to have a potential for use as a complementary test to improve surveillance program performance.
引用
收藏
页码:606 / 611
页数:6
相关论文
共 50 条
  • [1] Serum p53 antibodies in patients with ulcerative colitis are associated with the development of colorectal neoplasia
    Inoue, N
    Yoshizawa, S
    Matsuoka, K
    Takaishi, H
    Ogata, H
    Iwao, Y
    Mukai, M
    Fujita, T
    Kawakami, Y
    Hibi, T
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S298 - S298
  • [2] Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis
    Yoshizawa, Shigeo
    Matsuoka, Katsuyoshi
    Inoue, Nagamu
    Takaishi, Hiromasa
    Ogata, Haruhiko
    Iwao, Yasushi
    Mukai, Makio
    Fujita, Tomonobu
    Kawakami, Yutaka
    Hibi, Toshifumi
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (07) : 865 - 873
  • [3] Clinical significance of serum P53 antibodies in patients with ulcerative colitis and its carcinogenesis
    Inoue, Nagamu
    Yoshizawa, Shigeo
    Matsuoka, Katsuyoshi
    Takaishi, Hiromasa
    Ogata, Haruhiko
    Iwao, Yasushi
    Mukai, Makio
    Fujita, Tomonobu
    Kawakami, Yutaka
    Hibi, Toshifumi
    GASTROENTEROLOGY, 2007, 132 (04) : A178 - A178
  • [4] P53 codon 72 polymorphism in patients affected with ulcerative colitis
    Vietri, Maria Teresa
    Riegler, Gabrlele
    Ursillo, Antonietta
    Caserta, Luigi
    Cioffi, Michele
    Molinari, Anna Maria
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (06) : 456 - 460
  • [5] p53 codon 72 polymorphism in patients affected with ulcerative colitis
    Maria Teresa Vietri
    Gabriele Riegler
    Antonietta Ursillo
    Luigi Caserta
    Michele Cioffi
    Anna Maria Molinari
    Journal of Gastroenterology, 2007, 42 : 456 - 460
  • [6] Clinical importance of serum p53 antibodies in surveillance program for colorectal cancer in patients with ulcerative colitis
    Yoshiawa, S
    Inoue, N
    Matsuoka, K
    Ogata, H
    Iwao, Y
    Fujita, T
    Kawakami, Y
    Hibi, T
    GASTROENTEROLOGY, 2005, 128 (04) : A572 - A572
  • [7] Serum p53 antibodies (ABS) in patients with ulcerative colitis (UC) are associated with the development of colorectal cancer and screening of p53 ABS by ELISA is useful in cancer surveillance program for UC patients
    Inoue, Nagamu
    Yoshizawa, Shigeo
    Matsuoka, Katusyoshi
    Takaishi, Hiromasa
    Ogata, Haruhiko
    Iwao, Yasushi
    Mukai, Makio
    Fujita, Tomonobu
    Kawakami, Yutaka
    Hibi, Toshfumi
    GASTROENTEROLOGY, 2006, 130 (04) : A3 - A3
  • [8] A high degree of aneuploidy, loss of p53 gene, and low soluble p53 protein serum levels are detected in ulcerative colitis patients
    Rosman-Urbach, M
    Niv, Y
    Birk, Y
    Smirnoff, P
    Zusman, I
    Morgenstern, S
    Schwartz, B
    DISEASES OF THE COLON & RECTUM, 2004, 47 (03) : 304 - 313
  • [9] Changes in expression of p53 and inflammatory factors in patients with ulcerative colitis
    Su, Hui
    Kang, Qian
    Wang, Haihong
    Yin, Hui
    Duan, Linghui
    Liu, Yuli
    Fan, Ruying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (04) : 2451 - 2456
  • [10] Serum p53 antibodies in patients with skin carcinomas
    Moch, C
    Moysan, A
    Lubin, R
    Soufir, N
    Gallisson, F
    Vilmer, C
    Venutolo, E
    Le Pelletier, F
    Janin, A
    Basset-Séguin, N
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (03) : 465 - 465